Thanks Anton. Timolol reduces production of aqueous humour, and Pilocarpine indirectly increases aqueous outflow through the trabecular meshwork. Prostaglandins increase aqueous outflow but through the uveoscleral pathway. They think the potential mechanism of IOP reduction by THC is by increased aqueous outflow through the trabecular meshwork which is responsible for the majority of outflow. Rho-kinase inhibitors and adenosine agonists have been clinically studied for years to target trabecular outflow, I'm not sure if any have been submitted for approval. Combinations are always a possibility - Nicox combined nitric oxide with latanoprost to create Vesneo to also target the trabecular meshwork.
I was mistaken about the prospectus. It isn't a secondary offering by existing shareholders, just registration of common stock for resale. It was my mistake, I should have read it more carefully.
News 
Market Data 
Discover 
